Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenzilumab + azacitidine for VEXAS syndrome
ACTRN12625000619448Phase 2Not yet recruiting
- Sponsor
- South Australian Health and Medical Research Institute
- Start
- Aug 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenzilumab and azacitidine in VEXAS syndrome (VEXAS), sponsored by South Australian Health and Medical Research Institute. Primary endpoint: Safety and tolerability. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
lenzilumabazacitidine
03
Conditions
VEXAS syndrome (VEXAS)
Beyond the preview
Go deeper on ACTRN12625000619448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000619448.